{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:30:06Z","timestamp":1790235006077,"version":"4.1.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Hypertension"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:p>We previously reported that overexpression of full-length periostin, Pn-1, resulted in ventricular dilation with enhanced interstitial collagen deposition in a rat model. However, other reports have documented that the short-form splice variants Pn-2 (lacking exon 17) and Pn-4 (lacking exons 17 and 21) promoted cardiac repair by angiogenesis and prevented cardiac rupture after acute myocardial infarction. The apparently differing findings from those reports prompted us to use a neutralizing antibody to selectively inhibit Pn-1 by blockade of exon 17 in a rat acute myocardial infarction model. Administration of Pn neutralizing antibody resulted in a significant decrease in the infarcted and fibrotic areas of the myocardium, which prevented ventricular wall thinning and dilatation. The inhibition of fibrosis by Pn neutralizing antibody was associated with a significant decrease in gene expression of fibrotic markers, including collagen I, collagen III, and transforming growth factor-\u03b21. Importantly, the number of \u03b1-smooth muscle actin\u2013positive myofibroblasts was significantly reduced in the hearts of animals treated with Pn neutralizing antibody, whereas cardiomyocyte proliferation and angiogenesis were comparable in the IgG and neutralizing antibody groups. Moreover, the level of Pn-1 expression was significantly correlated with the severity of myocardial infarction. In addition, Pn-1, but not Pn-2 or Pn-4, inhibited fibroblast and myocyte attachment, which might account for the cell slippage observed during cardiac remodeling. Collectively, these results indicate that therapeutics that specifically inhibit Pn exon-17, via a neutralizing antibody or drug, without suppressing other perisotin variants might offer a new class of medication for the treatment of acute myocardial infarction patients.<\/jats:p>","DOI":"10.1161\/hypertensionaha.115.06265","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T20:44:43Z","timestamp":1449607483000},"page":"356-361","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":61,"title":["Selective Blockade of Periostin Exon 17 Preserves Cardiac Performance in Acute Myocardial Infarction"],"prefix":"10.1161","volume":"67","author":[{"given":"Yoshiaki","family":"Taniyama","sequence":"first","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Katsuragi","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiro","family":"Sanada","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Azuma","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Iekushi","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobutaka","family":"Koibuchi","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Okayama","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Ikeda-Iwabu","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Muratsu","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rei","family":"Otsu","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Gene Therapy (Y.T., N.K., F.S., J.A., K.I., N.K., K.O., Y.I.-I., J.M., R.O., R.M.) and Department of Geriatric Medicine and Nephrology (Y.T., J.A., K.I., H.R.), Osaka University, Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90456-B"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90574-0"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1042\/bj2940271"},{"key":"e_1_3_4_5_2","first-page":"5358","article-title":"Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility.","volume":"62","author":"Gillan L","year":"2002","unstructured":"Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002;62:5358\u20135364.","journal-title":"Cancer Res"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2005.11.002"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009426107"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.02.016"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-013-1494-y"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.20115"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40973"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.106.080994"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000142607.33398.54"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.107.149047"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.188649"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.01.009"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1619"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2011.712"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.9.3992-4003.2004"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603431"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/172460080802300308"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2010.07.008"},{"key":"e_1_3_4_23_2","first-page":"868","article-title":"The alpha-smooth muscle actin-positive cells in healing human myocardial scars.","volume":"145","author":"Willems IE","year":"1994","unstructured":"Willems IE, Havenith MG, De Mey JG, Daemen MJ. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am J Pathol. 1994;145:868\u2013875.","journal-title":"Am J Pathol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071297"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.67.1.23"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12607024"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-4889(99)00093-2"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.7.1239"}],"container-title":["Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/HYPERTENSIONAHA.115.06265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T05:51:54Z","timestamp":1715579514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/HYPERTENSIONAHA.115.06265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1161\/HYPERTENSIONAHA.115.06265"],"URL":"https:\/\/doi.org\/10.1161\/hypertensionaha.115.06265","relation":{},"ISSN":["0194-911X","1524-4563"],"issn-type":[{"value":"0194-911X","type":"print"},{"value":"1524-4563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"2015-08-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}